Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor that is in phase 1a/b clinical trial for the treatment of ulcerative colitis, as well as under phase 1a clinical trial for the treatment of fibrostenotic crohn's disease. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company is headquartered in Carlsbad, California. Show more

Location: 7750 El Camino Real, Carlsbad, CA, 92009, United States | Website: https://www.palisadebio.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

320.8M

52 Wk Range

$0.53 - $3.30

Previous Close

$2.15

Open

$2.17

Volume

1,665,417

Day Range

$2.00 - $2.17

Enterprise Value

332.9M

Cash

5.227M

Avg Qtr Burn

-2.521M

Insider Ownership

0.02%

Institutional Own.

40.90%

Qtr Updated

09/30/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
PALI-2108 Details Ulcerative colitis	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PALI-2108 Details Fibrostenotic Crohn’s Disease	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.